Cardiology Pharmaceuticals September 4, 2025
The Differences in HCM, ODYSSEY vs. MAPLE September 4, 2025
In a big step towards better hypertrophic cardiomyopathy treatments, two separate studies presented at ESC suggest cardiac myosin inhibitors’ efficacy depends critically on whether patients have the obstructive or nonobstructive form of the disease. Two similar but different trials presented contrasting outcomes at ESC 2025, with MAPLE-HCM testing aficamten versus metoprolol in obstructive HCM patients, […]
Cardiology August 28, 2025
Cardiologists, Practice What You Preach! August 28, 2025
Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]
Obesity Care August 25, 2025
GLP-1s Work, But Not for Free August 25, 2025
Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]
Electrophysiology August 21, 2025
Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025
Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]
Cardiology Pharmaceuticals August 18, 2025
Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025
New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]
Surgeries & Interventions August 14, 2025
TEER Could Save Lives in AFMR Patients August 14, 2025
Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]
Cardiology Business August 11, 2025
The State of the TAVR Market in 2025 August 11, 2025
2025 has been a year of many cardiology trends, with one stand out technology capturing much of the spotlight – transcatheter aortic valves. To keep our valves in a row, Cardiac Wire has compiled a breakdown of the top TAVR makers, movers, shakers, and potential future players. Starting off with the biggest player, Edwards Lifesciences […]
Cardiology Pharmaceuticals August 7, 2025
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes August 7, 2025
The largest and longest tirzepatide study to date just confirmed that Eli Lilly’s Mounjaro has surpassed its older GLP-1, Trulicity, in practically every way, with significant gains when it comes to cardiovascular benefits. The SURPASS-CVOT study represents the most comprehensive incretin analysis to date, comparing MACE rates in 13k T2D patients with ASCVD on either […]
Cardiovascular Disease August 4, 2025
The Impact of Physical Activity Before and After CV Events August 4, 2025
A long-term analysis of the CARDIA study revealed that moderate-to-vigorous physical activity steadily declines from young adulthood through midlife, but patients destined to develop cardiovascular disease experience rapid activity decreases more than a decade before their first event. Collecting data over 37 years, researchers tracked ~3k participants from young adulthood to middle age and paired […]
Cardiology Pharmaceuticals July 31, 2025
AstraZeneca’s Anselamimab Comes Up Short in Phase 3 Trial July 31, 2025
In a setback to one of its rarer disease pipelines, AstraZeneca’s amyloidosis antibody, anselamimab, failed to significantly reduce all-cause mortality and CV hospitalizations in the CARES Phase 3 trial’s overall patient population. The CARES clinical program was the largest prospective cardiac AL amyloidosis investigation to date, enrolling 406 patients to test whether anselamimab could reduce […]
Cardiology Pharmaceuticals July 28, 2025
SGLT2i Prescriptions Increase for HF, With Some Exceptions July 28, 2025
Three years after SGLT2 inhibitors were added to the heart failure treatment guidelines, a JAMA Cardiology study reveals significant new prescriptions, with a few key patient sub-groups falling behind. Researchers analyzed prescribing patterns of SGLT2 inhibitors for 760k HF patients in the National Cardiovascular Data Registry and found significant and rapid uptake in the last […]
Cardiac Imaging July 24, 2025
The Top Trends of SCCT 2025 July 24, 2025
The Society of Cardiovascular Computed Tomography had its 20th annual meeting in the gorgeous city of Montreal and though it’s still intimate, the conference punches well above its weight class when it comes to innovation. Here are some of the big takeaways from SCCT 2025. It’s About A Lot More Than Just Scanners – While […]
Cardiovascular Disease July 21, 2025
CV Polypills Could Prevent Millions of Deaths by 2050 July 21, 2025
A new JACC study revealed that broader adoption of single-pill combination therapies (aka polypills) containing multiple cardiovascular medications could significantly transform global health trends by 2050 and potentially lower the burden of future CVD. To predict the benefits of polypills, researchers modeled two different implementation strategies, a targeted and a population level approach. For the […]
Cardiology Pharmaceuticals July 17, 2025
It’s Official – Finerenone is Approved for HF July 17, 2025
One of the hardest-to-treat cardiac conditions just got a little more hopeful as the FDA approved Bayer’s KERENDIA (finerenone) for treating heart failure patients with left ventricular ejection fraction ≥40%, marking the first new pharmaceutical option for HF in years. While not originally intended for HF, KERENDIA’s approval stems from the 6k patient Phase III […]
Cardiovascular Disease July 14, 2025
Good News and Bad News – CV Deaths Are Changing July 14, 2025
Good news – overall heart disease deaths in the U.S. have declined significantly since 1970. The bad news? According to a recent AHA study, several complex heart conditions are becoming increasingly responsible for cardiovascular deaths. Searching for trends in CV mortality, Stanford researchers analyzed over 50 years of CDC data, revealing dramatic changes in cardiac […]
Cardiology July 10, 2025
Top 6 Cardiology Trends from 2025’s First Half July 10, 2025
The first half of 2025 is now over, and the world of cardiology keeps expanding. As we do every year, we’ve compiled a list of the top six stories of H1 – one for each month – to recap the big changes and innovations happening in cardiology. AI-ECG’s Hot Start and Fast Expansion 2025 kicked […]
Electrophysiology July 3, 2025
Kardium’s Quarter Billion Dollar PFA Raise July 3, 2025
Developing the best pulsed field ablation system in the world isn’t cheap, and Kardium’s new $250M financing round signals that the company now has enough funding to pursue that mission to its fullest. The fresh funding round follows impressive clinical data from Kardium’s PULSAR study presented at HRS 2025 that demonstrated the Globe System’s effectiveness […]
Structural Heart June 30, 2025
Foldax’s TRIA Mitral Valve Impresses at NYV June 30, 2025
The valve replacement space keeps adding contenders, and Foldax’s polymer-based TRIA Mitral Valve replacement showed compelling one-year results in its India Clinical Trial presented at New York Valves 2025, suggesting we could soon have an alternative to bovine tissue valves. Researchers tested the new surgical TRIA polymer valve on 67 patients (aged 19 to 67) […]
Population Health June 26, 2025
Save the Planet to Save Our Hearts (From Microplastics) June 26, 2025
We’ve all cut down on plastic straws to save the sea turtles, but what about ourselves? A recent AHA study suggests there could be a link between ocean microplastic levels and cardiovascular disease in U.S. coastal counties, adding to a concerning trend of microplastics and CV risk. Researchers analyzed counties near waters with high and […]
